Back

Metabolic associated fatty liver disease increases risk of adverse events after acute coronary syndrome.

29 August 2022 (11:50 - 12:00)
Organised by:
Congress Presentation Part of: What defines risk in acute coronary syndromes Clinical ESC Professional Premium Access ESC Congress 2022

About the speaker

Photo
Doctor Nicholas Chew

National University Health System, Singapore (Singapore)

5 More presentations in this session

Presentation thumbnail
Bleeding risk in patients hospitalized for non-ST-segment elevation acute coronary syndromes in Switzerland: performance of the CRUSADE score
Doctor F. Wenzl (Zurich, CH)
Abstract Slides Video
Presentation thumbnail
Clinical risk scores versus simple integrated clinical judgment in patients with suspected acute coronary syndromes
Doctor J. Boeddinghaus (Basel, CH)
Abstract Slides Video
Presentation thumbnail
Sex inequities in the performance of the GRACE 2.0 score in non-ST-segment elevation acute coronary syndromes: a multinational observational study in contemporary cohorts from four European countries
Doctor F. Wenzl (Zurich, CH)
Abstract Slides Video
Presentation thumbnail
Long-term non-cardiovascular morbidity risk remains elevated following myocardial infarction: a nationwide cohort study
Doctor D. Christensen (Herlev, DK)
Abstract Slides Video
Presentation thumbnail
Association of ischemic and bleeding events with mortality in patients with a recent acute myocardial infarction
Ms M. Simonsson (Stockholm, SE)
Abstract Slides Video

Access the full session

Session thumbnail
What defines risk in acute coronary syndromes
Video

The Event

Event poster

ESC Congress 2022

29 August 2022 11:50 CET
You may be interested in
thumbnail
Congress Presentation
The prognostic value of metabolic dysfunction associated steatotic liver disease in acute myocardial infarction
thumbnail
Congress Presentation
Prognostic outcomes of masld and obesity in acute myocardial infarction
thumbnail
Congress Presentation
Incremental prognostic value of metabolic dysfunction-associated fatty liver disease over coronary computed tomography angiography findings in patients with suspected coronary artery disease

ESC 365 is supported by

novartis Explore sponsored resources

ESC 365 is supported by

novartis Explore sponsored resources